BANNOCKBURN, Ill., April 18, 2012 /PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries.
Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer. Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities.
Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer. Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.
About Pinnacle Biologics
Pinnacle Biologics Inc., a privately held bio-pharmaceutical company, specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. The company is based in the U.S.A with its headquarters in Bannockburn, Illinois; and its European subsidiary, Pinnacle Biologics BV,is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.
About Bioprojet Pharma
Bioprojet Pharma is a privately held European pharmaceutical company with is headquarters in Paris, France. Bioprojet is a leading European research based specialty pharmaceutical company involved in the design and development of compounds from pre-clinical to Phase III. The company markets pharmaceutical products across Europe.
Pinnacle Biologics Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
|SOURCE Pinnacle Biologics Inc.|
Copyright©2010 PR Newswire.
All rights reserved